Investor/Media Center


Bio-Path is a biotechnology company focused on developing therapeutic products utilizing its proprietary liposomal delivery technology designed to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous infusion.   Bio-Path’s lead product candidate, Liposomal Grb-2, will soon enter Phase II clinical trials for blood cancers and is in pre-clinical studies for triple negative and inflammatory breast cancers. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors. These product candidates have been licensed from the MD Anderson Cancer Center.

Company Highlights

Bio-Path at-a-Glance

Focus: Drug delivery for nucleic acid drugs
Shares Outstanding: 89.8 million
Cash (at 12/31/15): 8.9 million
Burn rate: approximately $1,000,000 per quarter excluding clinical trial costs
Headquarters: Houston, TX
President and CEO: Peter Nielsen


  • Proprietary delivery technology may be breakthrough for antisense drugs, potentially solving the challenges of delivering these molecules directly to target cells, without side effects, which will dramatically change the treatment of cancer and other disease
  • Technology licensed from MD Anderson Cancer Center; maintains strong relationship with the Cancer Center
  • Strong IP position with composition of matter patents for antisense
  • Lead product candidate (Liposomal Grb-2) in clinic for blood cancers and in development for triple negative and inflammatory breast cancers. Second product candidate is IND-ready
  • Encouraging initial clinical data for Liposomal Grb-2 shows that the drug has been well tolerated and possible anti-leukemia effects have been observed
  • Importantly, patients in our trial with very advanced stages of leukemia have been stabilized from treatment with the drug Liposomal Grb-2, and stayed on treatment for extended periods.